VCYT Quote, Financials, Valuation and Earnings

Fonar has a net margin of 6.16% compared to Veracyte's net margin of 9.23%. Veracyte's return on equity of 2.85% beat Fonar's return on equity of 5.33%.

Veracyte has a consensus price target of $40.50, signalling upside risk potential of 49.12%. On the other hand Fonar has an analysts' consensus of -- which suggests that it could fall by --. Given that Veracyte has higher upside potential than Fonar, analysts believe Veracyte is more attractive than Fonar.

Veracyte has a beta of 2.145, which suggesting that the stock is 114.466% more volatile than S&P 500. In comparison Fonar has a beta of 1.003, suggesting its more volatile than the S&P 500 by 0.30600000000001%.

Veracyte has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Fonar offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Veracyte pays -- of its earnings as a dividend. Fonar pays out -- of its earnings as a dividend.

Veracyte quarterly revenues are $114.5M, which are larger than Fonar quarterly revenues of $27.2M. Veracyte's net income of $7M is higher than Fonar's net income of $2.5M. Notably, Veracyte's price-to-earnings ratio is 66.24x while Fonar's PE ratio is 11.42x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Veracyte is 4.63x versus 0.88x for Fonar. Usually stocks with elevated PS ratios are considered overvalued.

OncoCyte has a net margin of 6.16% compared to Veracyte's net margin of -312.02%. Veracyte's return on equity of 2.85% beat OncoCyte's return on equity of -693.81%.

Veracyte has a consensus price target of $40.50, signalling upside risk potential of 49.12%. On the other hand OncoCyte has an analysts' consensus of $5.42 which suggests that it could grow by 66.67%. Given that OncoCyte has higher upside potential than Veracyte, analysts believe OncoCyte is more attractive than Veracyte.

Veracyte has a beta of 2.145, which suggesting that the stock is 114.466% more volatile than S&P 500. In comparison OncoCyte has a beta of 0.953, suggesting its less volatile than the S&P 500 by 4.749%.

Veracyte has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. OncoCyte offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Veracyte pays -- of its earnings as a dividend. OncoCyte pays out -- of its earnings as a dividend.

Veracyte quarterly revenues are $114.5M, which are larger than OncoCyte quarterly revenues of $2.1M. Veracyte's net income of $7M is higher than OncoCyte's net income of -$6.7M. Notably, Veracyte's price-to-earnings ratio is 66.24x while OncoCyte's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Veracyte is 4.63x versus 14.73x for OncoCyte. Usually stocks with elevated PS ratios are considered overvalued.

ProPhase Labs has a net margin of 6.16% compared to Veracyte's net margin of -209.38%. Veracyte's return on equity of 2.85% beat ProPhase Labs's return on equity of -144.22%.

Veracyte has a consensus price target of $40.50, signalling upside risk potential of 49.12%. On the other hand ProPhase Labs has an analysts' consensus of $13.80 which suggests that it could grow by 3733.33%. Given that ProPhase Labs has higher upside potential than Veracyte, analysts believe ProPhase Labs is more attractive than Veracyte.

Veracyte has a beta of 2.145, which suggesting that the stock is 114.466% more volatile than S&P 500. In comparison ProPhase Labs has a beta of -0.472, suggesting its less volatile than the S&P 500 by 147.175%.

Veracyte has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ProPhase Labs offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Veracyte pays -- of its earnings as a dividend. ProPhase Labs pays out -- of its earnings as a dividend.

Veracyte quarterly revenues are $114.5M, which are larger than ProPhase Labs quarterly revenues of $1.4M. Veracyte's net income of $7M is higher than ProPhase Labs's net income of $4M. Notably, Veracyte's price-to-earnings ratio is 66.24x while ProPhase Labs's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Veracyte is 4.63x versus 1.95x for ProPhase Labs. Usually stocks with elevated PS ratios are considered overvalued.

XWELL has a net margin of 6.16% compared to Veracyte's net margin of -67.19%. Veracyte's return on equity of 2.85% beat XWELL's return on equity of -153.74%.

Veracyte has a consensus price target of $40.50, signalling upside risk potential of 49.12%. On the other hand XWELL has an analysts' consensus of -- which suggests that it could grow by 678.38%. Given that XWELL has higher upside potential than Veracyte, analysts believe XWELL is more attractive than Veracyte.

Veracyte has a beta of 2.145, which suggesting that the stock is 114.466% more volatile than S&P 500. In comparison XWELL has a beta of 1.014, suggesting its more volatile than the S&P 500 by 1.396%.

Veracyte has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. XWELL offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Veracyte pays -- of its earnings as a dividend. XWELL pays out -- of its earnings as a dividend.

Veracyte quarterly revenues are $114.5M, which are larger than XWELL quarterly revenues of $7M. Veracyte's net income of $7M is higher than XWELL's net income of -$4.7M. Notably, Veracyte's price-to-earnings ratio is 66.24x while XWELL's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Veracyte is 4.63x versus 0.14x for XWELL. Usually stocks with elevated PS ratios are considered overvalued.